is tirzepatide the same as zepbound vs Mounjaro: Drug, Different Uses tirzepatide 5 mg/0.5ml solution pen-injector

2026 National Medical Resources, Inc

ATTAIN-1 (NCT05869903) was a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes

No weight-loss plateau was observed, with participants continuing their weight loss trajectory through 40 weeks

GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review